In a small study, newly diagnosed chronic myeloid leukemia (CML) patients showed disruption in daily core clock gene expression patterns, which were then partially reversed in those that displayed cytogenetic and molecular response to imatinib treatment (64). This evidence concerns the gene CLOCK and chronic myelogenous leukemia, BCR-ABL1 positive.